Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: A meta-analysis

Nuclear Medicine Communications

Volumn 30, Issue 8, 2009, Pages 639-650

  Dong, Meng Jie ^a   Liu, Zhen Feng ^a   Zhao, Kui ^a   Ruan, Ling Xiang ^a   Wang, Guo Lin ^a   Yang, Shu Ye ^a   Sun, Fang ^a   Luo, Xu Guang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Differentiated thyroid carcinoma; FDG PET; FDG PET CT; Meta analysis; Radioiodine scintigraphy

Indexed keywords

DEPREOTIDE TC 99M; FLUORODEOXYGLUCOSE F 18; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; DIAGNOSTIC AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCINTISCANNING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; METASTASIS; SYSTEMATIC REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; WHOLE BODY SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; THYROID TUMOR; WHOLE BODY IMAGING;

FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 68349111689     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832dcfa7     Document Type: Article

References (45)

1. Mirallié E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 2007; 142:952-958. (Pubitemid 350193249)
2. Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 2007; 17:3139-3147. (Pubitemid 350147679)
3. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488-1492.
4. Uematsu H, Sadato N, Ohtsubo T, Tsuchida T, Nakamura S, Sugimoto K, et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 1998; 39:453-459. (Pubitemid 28136843)
5. Matsuno N, Minoshima S, Imazeki K. Diagnostic values of F18-FDG PET in primary and metastatic thyroid cancer. J Nucl Med 1995; 36:196P.
6. Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL. Combined [18F] fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 2008; 15:286-292.
7. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42:71-76. (Pubitemid 32104780)
8. Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 2000; 179:457-461. (Pubitemid 30742403)
9. Ong SC, Ng DC, Sundram FX. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Singapore Med J 2005; 46:297-301. (Pubitemid 40756546)
10. Zimmer LA, McCook B, Meltzer C, Fukui M, Bascom D, Snyderman C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003; 128:178-184. (Pubitemid 36314864)
11. Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX, Liu ZF, et al. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Nucl Med Commun 2008; 29:791-802.
12. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189. (Pubitemid 30464000)
13. 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44:1301-1314.
14. Cochrane methods group on systematic review of screening and diagnostic tests: recommended methods. Updated 6 June 1996. Available at: www.cochrane.org/cochrane/sadtdoc1.htm. [Accessed 27 August 2003]
15. Kim SJ, Lee TH, Kim IJ, Kim YK. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol 2009; 70:17-24.
16. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47:616-624. (Pubitemid 46768462)
17. 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab 2006; 91:3997-4000.
18. 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2004; 31:491-498.
19. 99mTc-EDDA/HYNIC-TOC and (18) F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging 2004; 31:330-341.
20. Hung MC, Wu HS, Kao CH, Chen WK, Changlai SP. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res 2003; 29:169-175. (Pubitemid 36828488)
21. Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC, et al. Preoperative diagnostic value of [(18) F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001; 234:804-811.
22. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, et al. Clinical impact of (18) F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131) I scanning results after therapy. J Nucl Med 2001; 42:1464-1469.
23. Yeo JS, Chung JK, So Y, Kim S, Lee E, Lee DS, et al. F-18- fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001; 23:94-103. (Pubitemid 32060661)
24. Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000; 128:1067-1074.
25. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41:1010-1015. (Pubitemid 30396649)
26. Stokkel MP, de Klerk JH, Zelissen PM, Koppeschaar HP, van Rijk PP. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 1999; 26:1606-1609.
27. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26:1547-1552. (Pubitemid 30010291)
28. 131I whole-body scan. J Nucl Med 1999; 40:986-992.
29. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131) I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-2302.
30. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schäfers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998; 383:160-163. (Pubitemid 28442531)
31. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24:1342-1348. (Pubitemid 27507513)
32. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37:1468-1472. (Pubitemid 26321624)
33. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23:312-319. (Pubitemid 26089112)
34. Crippa F, Alessi A, Gerali A, Bombardieri E. FDG-PET in thyroid cancer. Tumori 2003; 89:540-543.
35. Khan N, Oriuchi N, Higuchi T, Zhang H, Endo K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003; 76:690-695. (Pubitemid 37287705)
36. 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma. Nucl Med Commun 2003; 24:959-961.
37. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28:910-914. (Pubitemid 17096461)
38. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 2003; 30:17-21.
39. Lazar V, Bidart JM, Caillou B, Caillou B, Lazar V, Frydman R, et al. Expression of the Na+/I symporter gene in human thyroid tumors: a comparison study with other thyroidspecific genes. J Clin Endocrinol Metab 1999; 84:3228-3234. (Pubitemid 30646949)
40. Grünwald F, Biersack HJ. FDG PET in thyroid cancer: thyroxine or not? J Nucl Med 2000; 41:1996-1998.
41. Davison JM, Stocker DJ, Montilla-Soler JL, Jurgens JS, Allen TW, Holley TS, et al. The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma. Clin Nucl Med 2008; 33:464-468.
42. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 2007; 32:690-695. (Pubitemid 47294862)
43. Aygun N. Imaging of recurrent thyroid cancer. Otolaryngol Clin North Am 2008; 41:1095-1106.
44. Zoller M, Kohlfuerst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007; 34:487-495.
45. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48:221-226. (Pubitemid 47555347)